Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
SOLTA MEDICAL INC (SLTM)
|
Add to portfolio |
|
|
|
| Price: |
$2.26
| | Metrics |
| OS: |
80.7
|
M
| |
1
|
% ROE
|
| Market cap: |
$182
|
M
| |
31
|
% ROIC
|
|
Net debt:
|
$19
|
M
| |
1.1
|
x Debt/EBITDA
|
|
EV:
|
$201
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$16.8
|
M
| |
12.0
|
x EV/EBITDA
|
|
EBIT
|
$8.0
|
M
| |
25.3
|
x EV/EBIT
|
| EPS |
$0.02
| |
119.5
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 |
| Revenues | 144.5 | 116.0 | 110.9 | 98.8 | 56.7 | 63.1 | 54.3 | 40.7 |
| Revenue growth | 24.6% | 4.6% | 12.3% | 74.3% | -10.2% | 16.2% | 33.6% | -19.3% |
| Cost of goods sold | 55.4 | 42.4 | 41.4 | 40.6 | 15.1 | 16.0 | 15.3 | 12.3 |
| Gross profit | 89.2 | 73.6 | 69.5 | 58.3 | 41.6 | 47.1 | 39.1 | 28.3 |
| Gross margin | 61.7% | 63.5% | 62.7% | 58.9% | 73.4% | 74.7% | 71.9% | 69.7% |
| Sales and marketing | 53.7 | 46.8 | 42.7 | 38.9 | 27.0 | 26.2 | 24.1 | 20.0 |
| Research and development | 20.5 | 16.1 | 16.3 | 16.2 | 9.5 | 9.1 | 9.6 | 8.9 |
| General and administrative | 18.6 | 17.4 | 14.9 | 14.7 | 13.7 | 11.3 | 10.0 | 7.4 |
| EBIT | -35.8 | -7.0 | -4.1 | -11.6 | -8.6 | 0.5 | -4.6 | -6.3 |
| EBIT margin | -24.7% | -6.1% | -3.7% | -11.7% | -15.1% | 0.8% | -8.5% | -15.6% |
| Pre-tax income | -37.8 | -7.5 | -1.8 | -11.3 | -16.4 | 3.1 | -3.9 | -7.5 |
| Income taxes | 0.2 | -6.2 | 0.2 | -0.1 | 0.0 | 0.3 | 0.0 | 0.0 |
| Tax rate | | 82.3% | | 0.9% | | 8.9% | 0.0% | 0.0% |
| Net income | -38.0 | -1.3 | -2.0 | -11.2 | -16.4 | 2.8 | -3.9 | -8.2 |
| Net margin | -26.3% | -1.1% | -1.8% | -11.3% | -28.9% | 4.4% | -7.2% | -20.3% |
| |
| Diluted EPS | ($0.59) | ($0.02) | ($0.03) | ($0.23) | ($0.67) | $0.11 | ($0.60) | ($2.25) |
| Shares outstanding (diluted) | 64.4 | 60.6 | 58.9 | 48.7 | 24.5 | 24.9 | 6.6 | 3.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|